A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Trial Profile

A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Carfilzomib (Primary) ; Panobinostat (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Dec 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2017.
    • 07 Oct 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
    • 07 Oct 2015 Planned End Date changed from 1 Jul 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top